{
  "docId": "019de076-34c7-7046-ba4a-b568cf89a7c9",
  "docSlug": "e7da6c89bd00edfe5ee10f12333167ff",
  "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 56,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide combines a biological pathway diagram with a clinical trial summary table to demonstrate proof of concept.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-34c7-7046-ba4a-b568cf89a7c9/13",
  "deckHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9",
  "deckJsonHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9.json",
  "deckAnchorHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.5,
        "y": 0.73
      },
      "kind": "callout",
      "text": "Total size of safety database > 500 patients (includes monotherapy and combinations)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8cbfc3aa-888d-418f-9bde-f8d8a73dcc27",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.45,
        "x": 0.02,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Biological pathway diagram showing Naporafenib, trametinib, rineterkib, and ribociclib interactions with the RAS/MAPK pathway.",
      "attrs": null,
      "subkind": "value-chain",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e24b10e-fea2-44c8-92ee-c9cfefa1c37d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.02,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Novartis Non-Confidential Materials; PoC = proof of concept",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b50450be-14e6-41b1-9147-3f0270847791",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.5,
        "x": 0.48,
        "y": 0.335
      },
      "kind": "table",
      "text": "Study (Trial #) | Description | N\nPh 1 FIH study (LXH254X2101) | Naporafenib dose escalation | 142\nPh 1b combo dose finding (LXH254X2102) | Dose-finding study | 241\nPh 2 combo study (LXH254C12201) | Evaluating efficacy | 134",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0edd7a7b-6f20-4ac2-a758-b71601b073d4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.96,
        "x": 0.02,
        "y": 0.02
      },
      "kind": "title",
      "text": "Naporafenib has been dosed in more than 500 patients to date, establishing its safety, tolerability, and preliminary PoC in multiple indications",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e958c370-c593-4fd8-b434-623672ac8f22",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 15,
      "from": 6,
      "beatId": "dba801b5-a4b0-4e64-a12d-ace71b366d55",
      "arcName": "Rags to Riches",
      "arcSlug": "rags-to-riches",
      "beatName": "Challenges in current cancer treatment and unmet needs",
      "beatSlug": "rags-to-riches-early-struggles",
      "evidence": "Slides 6-15 discuss current treatment limitations and unmet needs in cancer",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}